Trustmark heads into its third-quarter report having done most of what it promised last time. Margins widened, deposit costs fell, credit got noticeably cleaner, and a core system that had been in place for 45 years was finally retired. Yet the stock has slipped about 4% since that report, trailing the S&P 500 by roughly 7 percentage points. The gap between the operating story and the share price frames this release. Management has already warned that the net interest margin will dip this quarter. That means loan growth, not margin, has to carry the earnings narrative.
Few semiconductor suppliers have delivered a sharper turn in their narrative than Ultra Clean Holdings, and few stocks have been punished as hard in the weeks since. Three months ago, management swapped its long-running wait-for-the-second-half message for a full-throated AI capacity story, guiding well above the Street and lifting its long-term capacity ambitions. The shares have since fallen nearly 47% while the S&P 500 barely moved. That gap frames the report due after the close on October 27: the operating story says acceleration, the stock price says doubt, and the third-quarter numbers will have to settle which view is closer to the truth.
Universal Health Services enters its third-quarter report with an awkward mismatch. Last quarter, management trimmed its full-year outlook and layered in a string of new headwinds. Since then, the stock has climbed nearly 24%, beating the S&P 500 by more than 20 percentage points. Investors have essentially bet that the guidance cut cleared the decks. The October 27 release, due after the close, is the first real chance to see whether that bet was right.
UMB Financial heads into its third-quarter report with a stock that has already run hard and an earnings bar that looks lower on the surface. Consensus calls for $3.22 a share, down from the $3.57 posted last quarter. That sequential dip is less a sign of trouble than a reflection of what flattered the second quarter: $27.1 million in private-investment gains tied to holdings such as Beacon and SpaceX. Strip those out, and the real question becomes whether the underlying bank, its margin, loan growth and institutional fee engine, can carry the stock's newly elevated valuation on its own.
Visa enters its fiscal fourth-quarter report with an awkward mismatch. Last quarter, management described a business accelerating on almost every front and raised its full-year outlook for the second straight time. At the same time, its own quarterly framework points below where Wall Street has landed, and the stock has rallied as if the stronger story is already settled. The October 27 release, due after the close, will show which of those signals deserves more weight.
Ventas has spent the past year doing almost everything a healthcare REIT can do to win over investors: raising funds from operations guidance three calls in a row, nearly doubling its acquisition target, and cutting leverage to its lowest level in more than a decade. Yet the stock has fallen 11.3% since the last report while the S&P 500 gained 3.7%. That gap sets up a report on October 27, after the close, that is less about whether Ventas can clear the bar and more about whether the summer leasing season justifies the confidence management projected three months ago.
Werner Enterprises heads into its third-quarter report with an unusual split in expectations. Published consensus calls for earnings of $0.37 per share, a big step up from the $0.22 the trucker posted last quarter, while the Earnings Whisper sits at just $0.16, below even the second-quarter result. That gap is too wide to dismiss. It suggests a meaningful slice of the market doubts the one-way turnaround can keep compounding at the pace sell-side models assume, and it sets up a report where the real test is not the printed estimate but whether the momentum from last quarter carried through the summer.
Waste Management enters its third-quarter report with a tension the market has not yet resolved. Last quarter the company cut its full-year revenue outlook because volumes kept disappointing, yet in the same breath it raised its margin target and reaffirmed its EBITDA and free cash flow plans. That is a bet that pricing, automation and cost discipline can carry earnings even when fewer tons move through the system. The coming report, due after the close on October 27, will show whether that bet is paying off or whether softer demand is starting to seep into profits.
W. P. Carey has spent the past year doing what income investors usually reward: raising guidance, cutting credit-loss assumptions and shoring up its balance sheet. The stock has gone the other way. Shares have fallen 15.5% since the last report while the S&P 500 gained 3.2%. That gap makes the third-quarter release, due after the close on October 27, a test of whether steady execution can still move a net-lease REIT that the market has largely written off for now.
Zurn Elkay heads into its third-quarter report with an awkward contradiction. Last quarter management raised full-year targets for EBITDA and free cash flow, posted its best margin since the merger and closed its first meaningful acquisition in years. Yet the stock has fallen 13.6% since then, trailing the S&P 500 by nearly 17 percentage points. The report due after the close on October 27 has to show that the self-help story still works as tariff-driven price gains fade from the top line.
Few stocks arrive at an earnings report with less goodwill banked than Lufax Holding. Shares have fallen 42% since the company last reported, a period in which the S&P 500 was essentially flat, and the stock now trades at $0.87, less than half its 200-day moving average of $1.80. The question for the third-quarter release, due after the close on October 27, is no longer whether the business can impress. It is whether it can show enough stability to stop the bleeding in the share price.
Automatic Data Processing heads into its fiscal first-quarter report with a stock near its highs and an earnings target that already asks for more than management promised for the full year. That is the central tension. ADP spent fiscal 2026 beating and raising, finishing at the high end of an outlook it had lifted along the way, and closed the year with its most confident tone in four calls. The first report of fiscal 2027 will show whether that momentum carries into a year management framed as one of slower top-line growth but continued margin gains.
American Electric Power heads into its third-quarter report with a quarterly earnings number that is almost secondary to what comes with it. Management promised last quarter to unveil its 2027-2031 capital plan on this call, with new generation as the centerpiece. After a year in which contracted load additions climbed from 28 gigawatts to 69 gigawatts, the question is no longer whether demand exists. It is how much of that demand AEP can turn into rate base, how fast, and at what financing cost.
AerCap enters its third-quarter report with an unusual mismatch. Management has raised its full-year profit outlook three times this year, yet the stock has slipped 6.6% since the last report while the S&P 500 gained 3.6%. The company keeps telling a story of tight aircraft supply, rising lease yields and record capital returns. The market seems more focused on whether the bonus from selling planes at fat premiums is starting to fade, and whether pressure from high fuel costs on airlines will eventually reach the lessor.
Aon heads into its third-quarter report with a striking disconnect between what management says and what the stock market believes. Last quarter the broker reaffirmed every one of its 2026 targets, expanded margins on schedule and bought back more stock in six months than it had promised for the full year. Since then the shares have fallen about 21%, trailing the S&P 500 by nearly 25 percentage points. The market is not questioning whether Aon can execute. It is questioning whether a turning insurance pricing cycle will quietly erode the organic growth that underpins the whole story.
Amphenol enters its third-quarter report riding a remarkable run: record sales, record margins, record orders, and a CommScope acquisition that is earning far more than management first promised. The question now is less about whether demand is strong and more about whether the company can keep turning a 1.23 book-to-bill into upside, even as its fastest-growing business cools from a sprint to a fast jog and its legacy telecom exposure softens.
Three months ago, Avantor finally gave investors what they had been waiting for: a guidance raise instead of another cut. Its VWR distribution business returned to organic growth a quarter ahead of plan, and management sounded confident enough to call 2027 a likely growth year. The stock has rallied hard since then. That shifts the third-quarter report, due before the open on October 28, from a show-me moment into a hold-the-line moment. The question is no longer whether the turnaround has started. It is whether it is durable enough to justify a share price that has already priced in much of the good news.
Axogen heads into its third-quarter report with a problem most medical device companies would envy and investors still distrust: demand is running ahead of plan, but the wrong kind of demand is eating into profitability. Last quarter management raised its revenue outlook for the third straight time while cutting its gross margin forecast, and the stock has spent the months since sliding toward the bottom of its post-earnings range. The October 28 release, due before the open, will show which half of that story the market should believe.
Three months ago Biogen did something it had not done in years: it told investors the top line would grow. Management flipped its full-year revenue outlook from a mid-single-digit decline to a mid-single-digit increase, closed the Apellis acquisition and secured approvals for high-dose Spinraza and the subcutaneous initiation option for Lekembe. The third-quarter report, due before the open on October 28, is the first real chance to see whether that turn holds up once the deals and launches are running for a full quarter.
Bausch + Lomb enters its third-quarter report with something it has not always had: credibility. Management has now strung together several quarters of doing what it said it would do, raising its full-year outlook twice and delivering an 8% constant-currency growth rate last quarter alongside a sharp margin expansion. The question for October 28 is whether that momentum holds as the calendar turns against it, with the second half of 2026 lapping a strong stretch from a year earlier.
Blackbaud enters its third-quarter report with a stock that has already decided the story is working. Shares have climbed 44% since the last release, against a 3.6% gain for the S&P 500, and at $53.24 they sit within a hair of their post-earnings high of $53.59. That rally has come even though the company's most visible growth metric has been moving the wrong way. Reported organic revenue growth slipped to 3% last quarter from 4.2% in the first quarter. The October 28 report, due before the open, has to show that the slowdown is the planned, temporary dip management described and not the start of something worse.
Boston Scientific heads into its third-quarter report with an unusual setup: Wall Street no longer seems to believe the company's own numbers. After three consecutive cuts to full-year guidance, analysts have pushed their quarterly estimates beneath management's stated range. The question on October 28 is less whether the medical device maker can beat a lowered bar and more whether its Watchman and electrophysiology franchises have stopped deteriorating.
Capitol Federal Financial heads into its next report with an earnings recovery that looks real on paper but has not earned much credit in the market. Wall Street expects the Kansas-based thrift to post $0.19 a share, matching the prior quarter and up roughly 36% from the $0.14 it earned a year ago. That is meaningful growth for a lender built on long-dated, fixed-rate home mortgages, a business that tends to change direction slowly. Yet the shares have drifted lower since the last report, and the question for this release is whether flat sequential earnings will read as a healthy plateau or as a sign that the improvement has stalled.
Three months ago, Chefs' Warehouse delivered the kind of quarter that changes how a stock is valued. Organic sales growth reaccelerated to 12.2%, gross margin widened by nearly half a point, and management raised its full-year outlook by roughly two quarters' worth of growth while lifting its long-range targets through 2030. The third-quarter report, due before the open on October 28, is the first real test of whether that step-up was the start of a durable inflection or a peak that the back half of the year was always going to cool.
C.H. Robinson heads into its third-quarter report with an awkward contradiction. Last quarter was, by most operating measures, the best the company has produced in a year: both major segments cleared their mid-cycle margin targets, adjusted gross profit swung back to growth, and management sounded more confident than at any point in recent memory. Yet the stock has fallen 14.2% since that report, trailing the S&P 500 by more than 18 percentage points. The October 28 release, due before the open, has to show whether the market is wrong about the earnings power or right about the risks.
Clean Harbors heads into its third-quarter report having raised its full-year profit outlook twice in a row, yet the stock has slipped since the last update. That disconnect frames the October 28 release. The market seems to be asking how much of the company's recent surge comes from a temporary spike in lubricant and base-oil prices, and how much reflects a sturdier environmental services engine that should keep compounding after the commodity tailwind fades.
Constellium heads into its third-quarter report with an unusual contradiction. Management has raised its full-year outlook three times in a row and now expects to reach its 2028 profit target two years early, yet the stock has dropped almost 13% since the last report while the S&P 500 gained close to 4%. The market appears to be pricing in the end of the good times before the company has reported them, which makes this quarter a test of how quickly the tailwinds behind record results are actually fading.
Dana enters its third-quarter report with a split personality. Its operating story has rarely looked better: margins are widening, heavy-truck demand has turned from headwind to tailwind, and the pending Eaton Mobility combination has redrawn the company's long-term ambitions. Yet the per-share earnings picture moved the other way last quarter. Management cut its full-year adjusted EPS outlook even as it raised sales, EBITDA and free cash flow targets. The October 28 report is the first real chance to see whether that gap between operating strength and bottom-line results is narrowing or widening.
Deutsche Bank heads into its third-quarter report with an odd disconnect. Three months ago management delivered its most confident message in years, nudging up full-year revenue and net interest income targets and unveiling the bank's first-ever intra-year buyback. Since then, the stock has fallen 11.5% while the S&P 500 gained 3.6%, and shares now sit at $31.63, essentially on the floor of their post-earnings range and well below the 200-day moving average near $35. The October 28 release, due before the open, is the bank's chance to show that the upgraded narrative is real and that the market has been too quick to fade it.
Diebold Nixdorf heads into its third-quarter report with a split personality. On the commercial side, the company has rarely looked better: first-half orders were the strongest in four years, retail revenue is growing at a pace few would have predicted from a legacy ATM maker, and banking hardware margins keep setting records. On the financial side, last quarter broke a streak that management had leaned on heavily, as free cash flow turned negative after six consecutive positive quarters, and memory chip costs began eating into product margins. The stock has absorbed that shift harshly, and Wednesday's pre-market release is the first chance to show whether the second half can deliver what the guidance now requires.
HF Sinclair heads into its third-quarter report with a peculiar setup: Wall Street expects earnings to climb well past last quarter's blowout even though the refiner told investors it would run less crude. That tension, between conflict-tightened fuel markets on one side and a planned September turnaround at El Dorado on the other, is the story of this report, which arrives before the market opens on October 28.
Brinker International heads into its fiscal first-quarter report with an odd disconnect. Management closed its last call sounding as confident as it has in years, telling investors that Chili's sales and traffic had accelerated meaningfully in July and August and issuing fiscal 2027 guidance that topped Street forecasts. Yet the stock has dropped 15.5% since then, trailing the S&P 500 by more than 14 percentage points. The report on October 28 is the first real chance to see whether that early-quarter momentum held up through September, and whether it was strong enough to absorb what management flagged as the heaviest commodity inflation of the year.
New Oriental heads into its fiscal first-quarter report with something unusual: a Street quarterly forecast that already runs hotter than management's full-year outlook. After three straight quarters of beat-and-raise results and a revenue growth curve that climbed from 6% to 23% over fiscal 2026, the question is no longer whether the recovery is real. It is whether the acceleration can hold at roughly 20% during the summer quarter, traditionally the period when the company earns the bulk of its profit, while the stock trades near its highest levels since the last report.
Equinor arrives at its third-quarter report with the market already convinced. The shares have climbed about 17% since the last release, beating the S&P 500 by roughly 14.5 percentage points. That rally rests on a June capital markets day that doubled the 2026 buyback to $3.0 billion and cut the after-dividend break-even by $10 to $50 a barrel. The question now is whether the September quarter backs up that swagger, or whether the operational blemishes management flagged in July start to show.
Etsy enters its third-quarter report with something it has lacked for years: momentum it can actually point to. Marketplace gross merchandise sales swung from a 2.4% decline a year ago to 7.5% growth last quarter, and management raised its full-year outlook for the third straight call. The question for the October 28 release is no longer whether Etsy can stop shrinking. It is whether the acceleration is durable enough to justify a stock that has already priced in a good deal of the recovery.
Evercore heads into its third-quarter report with an awkward mismatch. On its last call, management described a franchise firing on most cylinders: record revenue, its best underwriting quarter ever and a backlog near record levels. The stock has since fallen almost 24% while the S&P 500 gained about 4%. Either the market is anticipating a pause that management did not flag, or it is overreacting to one ugly quarter of expenses. This report should help show which.
Extreme Networks heads into its fiscal first-quarter report with a peculiar disconnect. Management closed fiscal 2026 with record profitability and guided to more than 20% earnings growth for fiscal 2027, yet the stock has fallen 18.3% since that report while the S&P 500 slipped only 1.2%. The market appears to have fixated on the other half of the message: revenue growth that is cooling, subscription ARR that is decelerating, and a full-year sales outlook below the company's own long-term framework. This quarter is the first real test of whether a margin-and-leverage story can carry the stock while the top line downshifts.
Franklin Electric left its last earnings call sounding more confident than it had all year, with a record quarter and its first guidance increase of 2026. The stock has gone the other way. Shares have fallen about 11% since that report while the S&P 500 gained nearly 4%. When the water and fuel pumping specialist reports third-quarter results before the open on October 28, the question is whether the business is cooling into the back half, or whether the market has marked down a story that is still intact.
Flex heads into its fiscal second-quarter report with an unusual disconnect. Last quarter, management raised its full-year outlook across revenue, earnings and every operating segment, posted margin expansion everywhere and described AI as a multi-year power and infrastructure story. Since then, the stock has fallen 12.5% while the S&P 500 gained 3.6%. The fundamentals told one story and the share price told another, and this report should show which one is closer to the truth.
FEMSA heads into its third-quarter report with the best operating story it has told in two years and a market that seems reluctant to believe it will last. Last quarter, OXXO Mexico posted positive customer traffic for the first time in eight quarters and same-store sales of roughly 9.5%, capping a steady climb from under 2% a year earlier. Management then did something unusual for a company on a roll: it told investors to expect less. Roughly 60% of the second-quarter lift came from the World Cup, executives said, and they steered second-half normalized comps back toward the mid-single digits. The October 28 release, due before the open, is the first clean look at what OXXO's momentum looks like without the soccer bump.
Fortive heads into its third-quarter report with an awkward split between story and stock. Last quarter the company delivered its first outright guidance raise since separating, with core growth climbing to 6.7% and adjusted EPS jumping 28%. Yet the shares have fallen 7.7% since that report while the S&P 500 gained 3.6%, a gap of more than 11 percentage points. The market appears to be looking past the acceleration and focusing on what management itself flagged: a muted third quarter and persistent gross-margin erosion.
GE HealthCare enters its third-quarter report with two very different stories running side by side. Last quarter, organic orders jumped 11.1%, the fastest pace since the company left General Electric, pushing backlog to a record $23.9 billion and book-to-bill to a record 1.15. At the same time, the Patient Care Solutions segment shrank 13.5% organically, posted negative segment profit and was placed under formal strategic review. The question for the October 28 release, due before the market opens, is whether the strong order book can start showing up in revenue and margins while PCS stops getting worse.
GE Vernova heads into its third-quarter report with an odd disconnect. Management has raised its full-year revenue outlook twice in two quarters, nearly doubled its free-cash-flow target, and lifted its long-term gas turbine capacity goals. Yet the stock has dropped 11% since the last report while the S&P 500 gained 2.7%. When the company reports before the open on October 28, the question is whether operating results can close that gap, or whether the market has spotted something the order book has not yet shown.
Generac enters its third-quarter report with an odd disconnect. Management spent the last call describing a data center business that is compounding at a remarkable pace, with backlog more than doubling in a single quarter and a second hyperscale agreement still waiting to be booked. Yet the stock has fallen 8% since that report while the S&P 500 gained 3.6%. The market is not disputing the data center story so much as asking how quickly it turns into revenue and margin, and whether a soft residential business can hold the line in the meantime.
Group 1 Automotive heads into its third-quarter report with a credibility test rather than a numbers test. Last quarter, management argued that much of the weakness in its US stores was temporary and partly its own doing, tied to a corporate rebranding that disrupted organic search traffic. Since then the stock has fallen about 29% while the S&P 500 gained roughly 4%. That suggests the market has largely rejected the idea that the slowdown will pass quickly. This report is where that argument either holds up or falls apart.
Three months ago Garmin did something it had resisted all year: it raised its full-year targets across the board. Revenue, earnings and both margin lines moved higher, and management swapped its earlier wait-and-see tone for open confidence. The third-quarter report, due before the market opens on October 28, is the first chance to see whether that confidence holds up once the costs management warned about start to appear. Those costs are higher memory prices, a weaker auto business and the loss of a one-time tariff refund.
GSK walks into its third-quarter report with an unusual message already on the record: profits are supposed to look worse this time. Management told investors last quarter that operating profit growth would be heavily weighted to the fourth quarter. The third quarter absorbs the first costs of consolidating the £7.1 billion Newvalent acquisition, the interest on the debt used to fund it and a tough tax comparison. That makes this report less about whether GSK grows earnings and more about whether the underlying business is strong enough to make the rest of the year's math work.
Hayward Holdings heads into its third-quarter report with a stock that has lost more than a quarter of its value since the last release, even though management reaffirmed its full-year outlook. That gap between steady guidance and a punishing share price frames the real question for the October 28 report, due before the market opens: was the second quarter's margin slip a temporary cost squeeze, or the start of a longer reversal after a year of steady expansion?
Hope Bancorp heads into its third-quarter report with a business that looks healthier than its stock price suggests. Last quarter, management delivered rising margins, loan growth that picked back up and a steadily improving efficiency ratio. Yet the shares have slipped since then while the broader market climbed, and trader sentiment has turned noticeably sour. That gap between operating momentum and market enthusiasm is the real story heading into the October 28 release, which arrives before the opening bell.
IDEX heads into its third-quarter report carrying something it has not had in a while: genuine momentum. Over three consecutive calls, management lifted its full-year organic growth outlook from 1% to 2% up to 5% to 6%, pushed its adjusted EPS range from $8.15 to $8.35 up to $8.70 to $8.85, and raised its margin target. Orders topped $1 billion for the first time. The question now is less about whether demand is real and more about how quickly that record backlog shows up in the income statement, and whether the nascent recovery in the company's short-cycle industrial businesses survived the summer.